Background: In patients with multiple sclerosis (MS), non-adherence to
disease-modifying drug therapy is associated with an increased rate of MS relapses.
Early identification of patients at risk of non-adherence would allow provision of timely
and individualized support. The aim of the BETAPREDICT study was to investigate
potential predictors of adherence in patients with MS in Germany treated with interferon
β-1b (IFNβ-1b) using the BETACONNECT® autoinjector.
Methods: BETAPREDICT was a national, multi-center, prospective, non-interventional,
single-arm, 24-month cohort study of patients with relapsing–remitting MS or
clinically isolated syndrome receiving IFNβ-1b via the BETACONNECT® autoinjector
(ClinicalTrials.gov: NCT02486640). Injection data were captured by the autoinjector. The
primary objective was to determine baseline predictors of compliance, persistence, and
adherence to IFNβ-1b treatment after 12- and 24 months using multivariable-adjusted
regression. Secondary objectives included evaluation of satisfaction with the autoinjector,
injection site pain, vitamin and nutrient supplementation, clinical course, and
patient-related outcome measures.
Results: Of 165 patients enrolled, 153 were available for analysis (120 with autoinjector
data). Seventy-two patients left the study prematurely. Compliance (N = 120),
persistence (N = 153), and adherence (N = 120) at 24 months were 89.1, 53.6,
and 41.7%, respectively. Compliance at 12- and 24 months was predicted by intake
of vitamin D supplements and absence of specific injection site reactions. Positive
predictors of persistence included age (at 12- and 24 months) and previous duration
of treatment (at 12 months), while intake of vitamins/nutrients other than vitamin D was
a negative predictor (at 12 months). Positive predictors of adherence at 24 months were
age and being experienced with IFNβ-1b. Higher scores in specific SF-36 subscales
were positive predictors of medication-taking behavior at 24 months. Satisfaction with
the autoinjector was high at baseline and 24 months (median score: 9 out of 10).
Conclusions: Compliance with IFNβ-1b treatment among participants still under
observation remained high over a 24-month period, while persistence and adherence
continuously declined. Multiple factors affected medication-taking behavior, including
patient characteristics, treatment history, injection site reactions, patients’ perception of
their health and support programs. The importance of these factors may differ among
patients according to their individual situation.
| Identifer | oai:union.ndltd.org:DRESDEN/oai:qucosa:de:qucosa:84333 |
| Date | 27 March 2023 |
| Creators | Köhler, Wolfgang, Bayer-Gersmann, Kirsten, Neußer, Thomas, Schürks, Markus, Ziemssen, Tjalf |
| Publisher | Frontiers Research Foundation |
| Source Sets | Hochschulschriftenserver (HSSS) der SLUB Dresden |
| Language | English |
| Detected Language | English |
| Type | info:eu-repo/semantics/publishedVersion, doc-type:article, info:eu-repo/semantics/article, doc-type:Text |
| Rights | info:eu-repo/semantics/openAccess |
| Relation | 1664-2295, 643126 |
Page generated in 0.002 seconds